Company: SMNR
Filing Date: 2025-07-02
Form Type: S-4/A
Source: 0001193125-25-154936
Chunk: 862

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-07-02
Form: S-4/A
Chunk 862
---
 10.12                              |     | Third Party Beneficiaries                               |     | A-1-57 |
| 10.13                              |     | Waiver                                                  |     | A-1-57 |
| 10.14                              |     | Non-Recourse                                            |     | A-1-57 |
| 10.15                              |     | Governing Law                                           |     | A-1-57 |
| 10.16                              |     | Jurisdiction                                            |     | A-1-58 |
| 10.17                              |     | Waiver of Jury Trial; Exemplary Damages                 |     | A-1-58 |
| 10.18                              |     | Company and Parent Disclosure Schedules                 |     | A-1-58 |
| 10.19                              |     | Conflicts and Privilege                                 |     | A-1-58 |
| 10.20                              |     | Counterparts; Signatures                                |     | A-1-59 |

LIST OF EXHIBITS

| Exhibit A |     | Form of Certificate of Incorporation            |
| Exhibit B |     | Form of Bylaws                                  |
| Exhibit C |     | Form of Registration Rights Agreement           |
| Exhibit D |     | Plan of Domestication                           |
| Exhibit E |     | Domesticated Parent Certificate of Designations |

A-1-iii

<div align='center'>**AGREEMENT AND PLAN OF MERGER**</div>

This AGREEMENT AND PLAN OF MERGER (the “Agreement”), dated as of August 30, 2024 (the “Signing Date”), is made and entered into by and among Denali Capital Acquisition Corp., a Cayman Islands exempted company (which shall migrate to and domesticate as a Delaware corporation prior to the Closing, “Parent”), Denali Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of Parent (“Merger Sub”), and Semnur Pharmaceuticals, Inc., a Delaware corporation (the “Company”).

<div align='center'>**W I T N E S E T H :**</div>

WHEREAS, the Company is a subsidiary of Scilex Holding Company, a Delaware corporation (“Scilex”), which is a publicly owned company listed on Nasdaq;

WHEREAS, the Company is in the business of identifying potential non-opioid pain therapy candidates, undertaking preclinical studies and clinical trials of its product candidate SP-102 and establishing research and development and